COPD Supplement to be Marketed as a Drug?
Chronic obstructive pulmonary disease (COPD) is the fastest growing cause of death in the world’s advanced economies. Such is the scale of the disease that the World Health Organization predicts it will be the third leading cause of death in the developed world by the year 2020—faster growing than lung cancer, heart disease and stroke.
The disease has reached epidemic proportions. It is estimated that up to 600 million people may suffer from COPD worldwide.
In response to the expected increase of COPD, Nature’s Bioceuticals has formulated a breathing aid made from natural herbs.
Robert deZanger, CEO of Nature’s Bioceuticals states, “We are excited to roll out our COPD formula. The market for our product is immense and the need is great. People afflicted with COPD have been prescribed repurposed asthma medicines to help them breathe. Our product should provide “natural relief” without the harmful side effects to millions of people with chronic breathing problems.”
Nature’s Bioceuticals management is currently determining whether to go through the time and expense of filing an Investigational New Drug (IND) Application and New Drug Application with the FDA for approval as a drug or to market the Formula as a nutritional supplement under the Dietary Supplement Health and Education Act of 1994 (DSHEA). If the formula is marketed under DSHEA the company will not be able to make any claims about the product treating, preventing or curing COPD or any disease.
For more information about Nature’s Bioceuticals, please click here.